Cytokines in the treatment and prevention of autoimmune responses - A role of IL-15

Advances in Experimental Medicine and Biology

Volumn 520, Issue , 2003, Pages 87-95

  Zheng, Xin Xiao ^a   Maslinski, Wlodzmierz ^a   Ferrari Lacraz, Sylvie ^a   Strom, Terry B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CELL FUNCTION; CELL MATURATION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 0038410262     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0171-8_6     Document Type: Review

References (70)

1. Oppenheim JJ, Feldmann M. The Cytokine Reference - A Comprehensive Guide to the Role of Cytokine in Health and Disease. London: Academic Press, 2000.
2. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1996; 8:872-877.
3. Feldmann M. The cytokine network in rheumatoid arthritis: Definition of TNF alpha as a therapeutic target. J R Coll Physicians Lond 1996; 30:560-570.
4. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14:397-440.
5. Brennan FM, Chantry D, Jackson A et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2:244-247.
6. Maini RN, Elliott MJ, Brennan FM et al. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995; 144:195-223.
7. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-9788.
8. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36:1681-1690.
9. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]. N Engl J Med 1999; 340:253-259.
10. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932-1939.
11. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and Methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602.
12. Markham A, Lamb HM. Infliximab: A review of its use in the management of rheumatoid arthritis. Drugs 2000; 59:1341-1359.
13. Editors G, Breedveld FC, Kalden JR et al. Advances in targeted therapies II [In Process Citation]. Ann Rheum Dis 2000; 59 Suppl 1:I.
14. van den Berg WB, Joosten LA, Kollias G et al. Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis 1999; 58 Suppl 1:I40.
15. Joosten LA, Helsen MM, van de Loo FA et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39:797-809.
16. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist [see comments]. Arthritis Rheum 1998; 41:2196-2204.
17. Jiang Y, Genant HK, Watt I et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-I receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43:1001-1009.
18. Bamford RN, Grant AJ, Burton JD et al. The interleukin 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 1994; 91:4940-4944.
19. Carson WE. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of IL-2 receptor. J Exp Med 1994; 180:1395-1403.
20. Girl JG. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBOJ 1994; 13:2822-2830.
21. Giri JG, Kumaki S, Ahdieh M et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. Embo J 1995; 14:3654-3663.
22. Smith KA. Interleukin-2: Inception, impact, and implications. Science 1988; 240:1169-1176.
23. Grabstein KH, Eisenman J, Shanebeck K et al. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Nature 1994; 264:965-968.
24. Anderson DM, Kumaki S, Ahdieh M et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 1995; 270:29862-29869.
25. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999; 17:19-49.
26. Meazza R, Gaggero A, Neglia F et al. Expression of two interleukin-15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides. Eur J Immunol 1997; 27:1049-1054.
27. Onu A, Pohl T, Krause H et al. Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J Immunol 1997; 158:255-262.
28. Tagaya Y, Kurys G, Thies TA et al. Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc Natl Acad Sci USA 1997; 94:14444-14449.
29. Musso T, Calosso L, Zucca M et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood 1999; 93:3531-3539.
30. Chae DW, Nosaka Y, Strom TB at al. Distribution of IL-15 receptor alpha-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression. J Immunol 1996; 157:2813-2819.
31. Lodolce JP, Boone DL, Chai S et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669-676.
32. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice [see comments]. J Exp Med 2000; 191:771-780.
33. Munger W, DeJoy SQ, Jeyaseelan R et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2. Cell Immunol 1995; 165:289-293.
34. Evans R, Fuller JA, Christianson G et al. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations. Cell Immunol 1997; 179:66-73.
35. Fehniger TA, Suzuk K, Ponnappan A. Fetal leukemia in interleukin-15 transgenic mice follows early expansion in NK and memory-phenotype CD8+ T cells. J Exp Med 2001; 193:219-232.
36. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: Implications for the innate immune response. J Immunol 1999; 162:4511-4520.
37. Ross ME, Caligiuri MA. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997; 89:910-918.
38. Bluman EM, Bartynski KJ, Avalos BR et al. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J Clin Invest 1996; 97:2722-2727.
39. Maghazachi AA, al-Aoukaty A, Schall TJ. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J Immunol 1994; 153:4969-4977.
40. Fahey TJd, Tracey KJ, Tekamp-Olson P et al. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1992; 148:2764-2769.
41. Kanegane H, Tosato G. Activation of naive and memory T cells by interleukin-15. Blood 1996; 88:230-235.
42. Zhang X, Sun S, Hwang I et al. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8:591-599.
43. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265:1225-1227.
44. Lenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257:789-792.
45. Buhlmann JE, Noelle RJ. Therapeutic potential for blockade of the CD40 ligand, gp39. J Clin Immunol 1996 ;16:83-89.
46. Mohan C, Shi Y, Laman JD et al. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154:1470-1480.
47. Jones ND, Van Maurik A, Hara M et al. CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection. J Immunol 2000; 165:1111-1118.
48. Newell KA, He G, Guo Z et al. CTLA4Ig fails to prevent intestinal allograft rejection due to an inability to inhibit CD8 T cell responses. Transplantation 1999; 67:s45.
49. Trambley J, Bingaman AW, Lin A et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104:1715-1722.
50. Schorle H, Holtschke T, Hünig T et al. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991; 352:621-623.
51. Willerford DM, Chen J, Ferry JA et al. Interleukin-2 receptor alpha chain regulates the size an content of the perpheral lymphoid compartment immunity. Immunity 1995; 3:521-530.
52. Suzuki H, Kunding TM, Furlonger C et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin receptor beta. Science 1995; 268:1472-1476.
53. Dooms H, Desmedt M, Vancaeneghem S et al. Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T cell responsiveness to antigen. J Immunol 1998; 161:2141-2150.
54. Bulfone-Paus S, Ungureanu D, Pohl T et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med 1997; 3:1124-1128.
55. Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5:1303-1307.
56. Li Y, Li XC, Zheng XX et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5:1298-1302.
57. Li XC, Demirci G, Ferrari-Lacraz S et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med 2001; 7:114-118.
58. Wooley PH, Dutcher J, Widmer MB et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-6607.
59. Williams RO, Ghrayeb J, Feldmann M et al. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995; 84:433-439.
60. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-1110.
61. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombiant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. N Engl J Med 1997; 337:141-147.
62. McInnes IB, Leung BP, Sturrock RD et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 1997; 3:189-195.
63. Ziolkowska M, Koc A, Luszczykiewicz G et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164:2832-2838.
64. Harada S, Yamamura M, Okamoto H et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42:1508-1516.
65. Wilkinson PC, and Liew FY. Chemoattraction of human blood T lymphocytes by interleukin-I5. J Exp Med 1995; 181:1255-1259.
66. McInnes IB, al-Mughales J, Field M et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis [see comments]. Nat Med 1996; 2:175-182.
67. Ruchatz H, Leung BP, Wei XQ et al. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology. J Immunol 1998; 160:5654-5660.
68. Zurawski SM, and Zurawski G. Receptor antagonist and selective agonist derivatives of mouse interleukin-2. EMBO J 1992; 11:3905-3910.
69. Kim YS, Maslinski W, Zheng XX et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol 1998; 160:5742-5748.
70. Zheng XX, Steele AW, Hancock WW et al. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol 1999; 163:4041-4048.